Furazabol

Furazabol
Clinical data
Trade names	Frazalon, Miotalon, Qu Zhi Shu
Other names	Androfurazanol; DH-245; Furazalon; Frazalon; Pirzalon; 17α-Methyl-5α-androsta[2,3-c]furazan-17β-ol; 17β-Hydroxy-17α-methyl-5α-androstano[2,3-c]-1',2',5'-oxadiazole; 17α-Methyl-5α-androstano[2,3-c][1,2,5]oxadiazol-17β-ol
Routes of; administration	By mouth
Drug class	Androgen; Anabolic steroid
ATC code	B ;
Legal status
Legal status	CA: Schedule IV; US: Schedule III;
Pharmacokinetic data
Elimination half-life	4 hours[citation needed]
Excretion	Urine
Identifiers
	IUPAC name (1S,2S,10S,13R,14S,17S,18S)-2,17,18-Trimethyl-6-oxa-5,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4,7-dien-17-ol;
CAS Number	1239-29-8 ;
PubChem CID	14708;
DrugBank	DB01514 ;
ChemSpider	14032 ;
UNII	2W07HSP5PX;
ChEMBL	ChEMBL1893554 ;
CompTox Dashboard (EPA)	DTXSID7046889 ;
ECHA InfoCard	100.013.621
Chemical and physical data
Formula	C20H30N2O2
Molar mass	330.472 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O[C@@]5([C@@]4([C@H]([C@H]3[C@@H]([C@]2(Cc1nonc1C[C@@H]2CC3)C)CC4)CC5)C)C;
	InChI InChI=1S/C20H30N2O2/c1-18-11-17-16(21-24-22-17)10-12(18)4-5-13-14(18)6-8-19(2)15(13)7-9-20(19,3)23/h12-15,23H,4-11H2,1-3H3/t12-,13+,14-,15-,18-,19-,20-/m0/s1 ; Key:RGLLOUBXMOGLDQ-IVEVATEUSA-N ;
	(what is this?) (verify)

Furazabol (INNTooltip International Nonproprietary Name, JANTooltip Japanese Accepted Name) (brand names Frazalon, Miotalon, Qu Zhi Shu), also known as androfurazanol, is a synthetic, orally active anabolic-androgenic steroid which has been marketed in Japan since 1969.^[1]^[2]^[3]^[4] It is a 17α-alkylated derivative of dihydrotestosterone (DHT) and is closely related structurally to stanozolol, differing from it only by having a furazan ring system instead of pyrazole.^[5] Furazabol has a relatively high ratio of anabolic to androgenic activity.^[4] As with other 17α-alkylated AAS, it may have a risk of hepatotoxicity.^[6] The drug has been described as an antihyperlipidemic and is claimed to be useful in the treatment of atherosclerosis and hypercholesterolemia,^[5] but according to William Llewellyn, such properties of furazabol are a myth.^[7]

^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 585–. ISBN 978-1-4757-2085-3.
^ Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 475–. ISBN 978-3-88763-075-1.
^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 1725–. ISBN 978-0-8155-1856-3.
^ ^a ^b Progress in Medicinal Chemistry. Elsevier. 1 January 1979. pp. 62–63. ISBN 978-0-08-086264-4.
^ ^a ^b Fragkaki AG, Angelis YS, Koupparis M, Tsantili-Kakoulidou A, Kokotos G, Georgakopoulos C (2009). "Structural characteristics of anabolic androgenic steroids contributing to binding to the androgen receptor and to their anabolic and androgenic activities. Applied modifications in the steroidal structure". Steroids. 74 (2): 172–97. doi:10.1016/j.steroids.2008.10.016. PMID 19028512. S2CID 41356223.
^ Abbate V, Kicman AT, Evans-Brown M, McVeigh J, Cowan DA, Wilson C, Coles SJ, Walker CJ (2015). "Anabolic steroids detected in bodybuilding dietary supplements - a significant risk to public health". Drug Test Anal. 7 (7): 609–18. doi:10.1002/dta.1728. PMID 25284752.
^ William Llewellyn (2007). Anabolics 2007: Anabolic Steroids Reference Manual. Body of Science. ISBN 978-0967930466.